Can therapeutic drug monitoring improve pharmacotherapy of hiv infection in adolescents?

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 273-281

  Rakhmanina, Natella Y ^a,b,c   Van Den Anker, John N ^b,c,d   Soldin, Steven J ^e   Van Schaik, Ron H ^f   Mordwinkin, Nick ^g   Neely, Michael N ^g,h  

^a Division of Infectious Diseases   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d Departments of Pediatrics   (United States)

^e GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^g Division of Pediatric Infectious Diseases   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adolescents; Efavirenz; HIV; Pharmacotherapy; TDM

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; AMPRENAVIR; AMYLASE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LIPID; LIVER ENZYME; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL LIPASE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; AREA UNDER THE CURVE; CASE REPORT; CONFERENCE PAPER; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SALIVA LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADOLESCENT; ANTI-HIV AGENTS; DRUG MONITORING; HIV INFECTIONS; HUMANS; YOUNG ADULT;

EID: 77952950989     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dca14b     Document Type: Conference Paper

References (57)

1. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Updated February 23, 2009. Available at: http://aidsinfo.nih.gov/contentfiles/PediatricGuidelines.pdf. Accessed November 27, 2009.
2. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834.
3. Back D, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS. 2002;16(Suppl 1): S5-S37.
4. Rakhmanina NY, Capparelli EV, van den Anker JN. Personalized therapeutics: HIV treatment in adolescents. Clin Pharmacol Ther. 2008;84:734-740.
5. Neely M, Jelliffe R. Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization. J Clin Pharmacol. 2008;48:1081-1091.
6. Fraaij PL, Rakhmanina N, Burger DM, et al. Therapeutic drug monitoring in children with HIV/AIDS. Ther Drug Monit. 2004;26:122-126. (Pubitemid 38501204)
7. Rakhmanina N, van den Anker J, Baghdassarian A, et al. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2009;53:2532-2538.
8. Hirt D, Urien S, Olivier M, et al. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother. 2009;53:4407-4413.
9. Van Dyke RB, Lee S, Johnson GM, et al. Report edadherenceasade terminant of response to highly active an tiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109:e61.
10. Rudy BJ, Murphy DA, Harris DR, et al. Patient-related risks for nonadherence to antiretroviral therapy among HIV-infected youth in the United States: a study of prevalence and interactions. AIDS Patient Care STDs. 2009;23:185-194.
11. Optimizing antiretroviral therapy in HIV-infected children and adolescents. NCT00207948. Available at: http://clinicaltrials.gov. Accessed November 27, 2009.
12. Aarnoutse RE, Verweij-van Wissen CP, van Ewijk-Beneken Kolmer EW, et al. International interlaboratory quality control program for measurement of antiretroviral drugs in plasma. Antimicrob Agents Chemother. 2002;46:884-886.
13. Droste JA, Koopmans PP, Hekster YA, et al. TDM: therapeutic drug measuring or therapeutic drug monitoring? Ther Drug Monit. 2005;27: 412-416.
14. Ghoshal AK, Soldin SJ. Improved method for concurrent quantification of antiretrovirals by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2003;25:541-543.
15. Volosov A, Alexander C, Ting L, et al. Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry. Clin Biochem. 2002;35:99-103.
16. Rakhmanina NY, Capparelli EV, van den Anker JN, et al. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther Drug Monit. 2007;29:110-117.
17. van Rossum AM, Bergshoeff AS, Fraaij PL, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:743-747.
18. Marhefka SL, Farley JJ, Rodrigue JR, et al. Clinical assessment of medication adherence among HIV-infected children: examination of the Treatment Interview Protocol (TIP). AIDS Care. 2004;16:323-338.
19. Murphy DA, Wilson CM, Durako SJ, et al. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13:27-40.
20. Simoni JM, Montgomery A, Martin E, et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics. 2007; 119:e1371-e1383.
21. Giannattasio A, Albano F, Giacomet V, et al. The changing pattern of adherence to antiretroviral therapy assessed at two time points, 12 months apart, in a cohort of HIV-infected children. Expert Opin Pharmacother. 2009;10:2773-2778.
22. Khan M, Song X, Williams K, et al. Evaluating adherence to medication in children and adolescents with HIV. Arch Dis Child. 2009;94:970-973.
23. Battles HB, Wiener LS. From adolescence through young adulthood: psychosocial adjustment associated with long-term survival of HIV. J Adolesc Health. 2002;30:161-168.
24. Pearson CR, Simoni JM, Hoff P, et al. Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues. AIDS Behav. 2007;11:161-173.
25. Hammami N, Nostlinger C, Hoeree T, et al. Integrating adherence to highly active antiretroviral therapy into children's daily lives: a qualitative study. Pediatrics. 2004;114:e591-e597.
26. Mutlib AE, Chen H, Nemeth GA, et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos. 1999;27:1319-1333.
27. Desta Z, Saussele T, Ward B, et al. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics. 2007;8: 547-558.
28. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther. 2003;306:287-300.
29. Bumpus NN, Kent UM, Hollenberg PF. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. J Pharmacol Exp Ther. 2006;318:345-351.
30. Saitoh A, Fletcher CV Brundage R, et al. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. JAcquir Immune Defic Syndr. 2007;45:280-285. (Pubitemid 47012374)
31. Puthanakit T, Tanpaiboon P, Aurpibul L, et al. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. Antivir Ther. 2009;14:315-320.
32. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391-2400.
33. Lowenhaupt EA, Matson K, Qureishi B, et al. Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis. 2007;45:e128-e130.
34. Wyen C, Hendra H, Vogel M, et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chemother. 2008; 61:914-918.
35. Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;81:557-566.
36. Kwara A, Lartey M, Sagoe KW, et al. CYP2B6 (c.516G->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br J Clin Pharmacol. 2009;67:427-436.
37. Gatanaga H, Hayashida T, Tsuchiya K, et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007;45:1230-1237.
38. Cabrera SE, Santos D, Valverde MP, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009;53:2791-2798.
39. Arab-Alameddine M, Di Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther. 2009;85:485-494.
40. van Luin M, Gras L, Richter C, et al. Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J Acquir Immune Defic Syndr. July 10, 2010 [Epub ahead of print].
41. Torno MS, Witt MD, Saitoh A, et al. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. Pharmacotherapy. 2008;28:782-787.
42. Lang T, Klein K, Richter T, et al. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of pheno-typic null alleles. J Pharmacol Exp Ther. 2004;311:34-43.
43. Nyakutira C, Roshammar D, Chigutsa E, et al. High prevalence of the CYP2B6 516G->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol. 2008;64:357-365.
44. Mehlotra RK, Ziats MN, Bockarie MJ, et al. Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. Eur J Clin Pharmacol. 2006;62:267-275.
45. Saitoh A, Sarles E, Capparelli E, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS. 2007;21:2191-2199.
46. van Luin M, Bannister WP, Mocroft A, et al. Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. Antivir Ther. 2009;14:75-83.
47. Powers V, Ward J, Gompels M. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. HIV Med. 2009;10:520-523.
48. Sustiva® Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company. August 2008.
49. Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006;42:1189-1196.
50. Cremieux AC, Katlama C, Gillotin C, et al. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults. Pharmacotherapy. 2001;21:424-430.
51. Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clin Pharmacokinet. 2008;47:351-371.
52. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs. 2005;65:413-432.
53. Gagnieu MC, Barkil ME, Livrozet JM, et al. Population pharmaco-kinetics of tenofovir in AIDS patients. J Clin Pharmacol. 2008;48: 1282-1288.
54. Villani P, Regazzi MB, Castelli F, et al. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol. 1999;48: 712-715.
55. Swainston Harrison T, Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs. 2005;65:2309-2336.
56. Molto J, Barbanoj MJ, Miranda C, et al. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin Pharmacokinet. 2008;47:681-692.
57. Crommentuyn KM, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005;60:378-389.